Swiss Biotech sector boosted by shift toward private funding, report says

Switzerland's biotech sector moved toward private financing in 2025 as public capital markets stayed challenging, according to the Swiss Biotech Report 2026. Total sector funding rose 2.1% to 2.6 billion CHF, with privately funded companies seeing a 38% jump and making up nearly half of funding. Pharmaceutical firms increasingly use R&D collaborations, licensing and funded partnerships rather than large acquisitions, a trend expected to continue. Sector revenue hit a record 7.5 billion CHF in 2025 as more companies commercialised and demand for specialised contract manufacturing grew. Product approvals slipped slightly in the US, Europe and Switzerland but rose in markets including China and Canada. Overall the report signals a resilient, if transforming, sector driven by private capital and partnerships.